Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

NCT00253370 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Gastroesophageal Junction
Metastatic Gastric Cancer
Advanced Unresectable Gastric Cancer

Interventions

DRUG: BAY 43-9006
DRUG: docetaxel
DRUG: cisplatin

Sponsor

National Cancer Institute (NCI)